

REVIEW ARTICLE OPEN



Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension

Ruben Willems¹✉, Lieven Annemans¹, George Siopis^{2,3}, George Moschonis², Rajesh Vedanthan⁴, Jenny Jung⁵, Dominika Kwasnicka^{6,7}, Brian Oldenburg⁶, Claudia d'Antonio⁸, Sandro Girolami⁸, Eirini Agapidaki⁹, Yannis Manios^{10,11}, Nick Verhaeghe¹¹ and DigiCare 4You*

Digital health interventions have been shown to be clinically-effective for type 2 diabetes mellitus (T2DM) and hypertension prevention and treatment. This study synthesizes and compares the cost-effectiveness of text-messaging, smartphone application, and websites by searching CINAHL, Cochrane Central, Embase, Medline and PsycInfo for full economic or cost-minimisation studies of digital health interventions in adults with or at risk of T2DM and/or hypertension. Costs and health effects are synthesised narratively. Study quality appraisal using the Consensus on Health Economic Criteria (CHEC) list results in recommendations for future health economic evaluations of digital health interventions. Of 3056 records identified, 14 studies are included (7 studies applied text-messaging, 4 employed smartphone applications, and 5 used websites). Ten studies are cost-utility analyses: incremental cost-utility ratios (ICUR) vary from dominant to €75,233/quality-adjusted life year (QALY), with a median of €3840/QALY (interquartile range €16,179). One study finds no QALY difference. None of the three digital health intervention modes is associated with substantially better cost-effectiveness. Interventions are consistently cost-effective in populations with (pre)T2DM but not in populations with hypertension. Mean quality score is 63.0% (standard deviation 13.7%). Substandard application of time horizon, sensitivity analysis, and subgroup analysis next to transparency concerns (regarding competing alternatives, perspective, and costing) downgrades quality of evidence. In conclusion, smartphone application, text-messaging, and website-based interventions are cost-effective without substantial differences between the different delivery modes. Future health economic studies should increase transparency, conduct sufficient sensitivity analyses, and appraise the ICUR more critically in light of a reasoned willingness-to-pay threshold.

Registration: PROSPERO (CRD42021247845).

npj Digital Medicine (2023)6:150; <https://doi.org/10.1038/s41746-023-00876-x>

INTRODUCTION

An estimated 537 million people, of which 44.7% undiagnosed, are nowadays living with diabetes mellitus worldwide. Type 2 Diabetes Mellitus (T2DM), formerly known as non-insulin-dependent or adult-onset diabetes, accounts for 90% of the population with diabetes¹. Additional estimates indicate 541 million people having impaired glucose tolerance and 319 million having impaired fasting glucose levels, otherwise defined as prediabetes¹, and are as such at increased risk to progress to T2DM².

T2DM often occur together with hypertension³, another major risk factor for cardiovascular disease. Regarding its prevalence, hypertension affects around 1.28 billion or one-third of all adults between 30 and 79 globally, with 46% of them being unaware of the condition (<https://www.who.int/news-room/fact-sheets/detail/hypertension>). Prevalence is

slightly decreasing in high-income countries but it is still on the rise in low- and middle-income countries⁴. An additional quarter to half of the global adult population is presumed to have pre-hypertension, defined as high normal office systolic and diastolic BP⁵.

Both diabetes and hypertension impose a substantial burden on healthcare budgets with 11.5 and 10% of global health expenditures spent on diabetes¹ and high BP⁴, respectively. It is encouraging that preventive measures targeting modifiable lifestyle risk factors could result in substantial health and economic gains^{1,6}. Lifestyle interventions focusing on diet modifications and increased physical activity have been proven effective in reducing HbA1c-levels and BP values⁷, and despite some discrepant results and varying study quality, these lifestyle interventions were found to be cost-effective as well^{8–10}. Lifestyle interventions are thus valid strategies but the cost-effectiveness of various programmes

¹Interuniversity Center of Health Economic Research (ICHER), department of Public Health and Primary Care, Ghent University, Ghent, Belgium. ²Department of Food, Nutrition and Dietetics, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia. ³Institute for Physical Activity and Nutrition, Deakin University, Geelong, Victoria, Australia. ⁴Department of Population Health, NYU Grossman School of Medicine, New York, USA. ⁵Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Australia. ⁶NHMRC CRE in Digital Technology to Transform Chronic Disease Outcomes, Baker Heart and Diabetes Institute, Melbourne, Australia. ⁷Faculty of Psychology, SWPS University of Social Sciences and Humanities, Wroclaw, Poland. ⁸Meteda S.r.l., Roma, Italy. ⁹Ministry of Health, Athens, Greece. ¹⁰Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece. ¹¹Institute of Agri-food and Life Sciences, Hellenic Mediterranean University Research Centre, Heraklion, Greece. *A list of authors and their affiliations appears at the end of the paper. ✉email: Ruben.Willems@ugent.be




Fig. 1 PRISMA flow diagram.

and their drivers still need to be better documented. Staff labour cost is such an important driver, accounting for the larger part of lifestyle intervention costs and could thus be a potential target for improving cost-effectiveness¹¹, for instance with the use of digital health interventions.

There is increasing evidence of digital health interventions as a practical, low labour and low cost delivery mode¹² that can foster clinical-effectiveness and cost-effectiveness of such lifestyle measures. The potential is great since 92% of the global population uses a mobile phone¹³. The clinical effectiveness of digital health in diabetes and hypertension management has been confirmed^{14–20} but limited cost-effectiveness data have been referred to as one of the major barriers for widespread implementation²¹. Yet, Iribarren et al.²² reported that 75% of full economic studies (i.e., a comparison of both costs and health consequences of two or more alternatives) in a broad range of conditions found cost-effective or cost-saving results for mobile health solutions. Specifically, for T2DM, previous systematic reviews focused mainly on partial economic evaluations (i.e., single programme description of both costs and health consequences, or cost description/analysis of one or more alternatives)^{23,24}. Nevertheless, the few full economic evaluations showed favourable results for digital health intervention modes such as phone/video calls, Short Message Service (SMS), and telemonitoring²³.

The current study aims to systematically review full health economic evaluations of digital health interventions targeting the prevention and treatment of T2DM and/or hypertension in adults with (pre)diabetes and/or (pre)hypertension: smartphone applications, text-messaging, and websites are the subject of investigation^{19,20}. This systematic review extends previously published systematic reviews that were mainly based on partial economic evaluations. Although such

evaluations can provide some trends in this field, it is critically important in rapidly evolving research fields, such as digital health, to synthesize and report on more comprehensive economic evaluations²⁵. The current systematic review focuses on three specific digital technology modes and discusses the health economic evidence for each mode separately. Finally, this review puts emphasis on the methodological quality appraisal, with a focus on making informed recommendations to improve methodological quality.

RESULTS

Study selection

The process of study identification, screening, and inclusion is displayed in the PRISMA flow diagram in Fig. 1. From 3056 studies (2503 after duplicate removal) identified through database searches, 14 studies evaluated the value for money of either website^{26–30}, text-messaging^{27,31–36}, or smartphone application interventions^{29,37–39}. An overview of study characteristics, intervention details, and health economic outcomes can be found in Table 1. Supplementary note 1 shows excluded studies at full text screening with reasons. Augustovski et al.³¹ and Zhang et al.³⁶ reported on the same trial but the former was a trial-based analysis while the latter was model-based to extrapolate costs and effects on the long-term.

Study characteristics

Included studies reflected a broad geographic distribution with one study conducted in North America²⁶, one in Central America³², two in South America^{31,36}, four in East Asia^{34,37–39}, one in South Asia³³, two in the Middle East^{30,35}, and three in Europe^{27–29}. Eight studies included people with

Table 1. Evidence table.

Study	Study characteristics				Intervention		Health economic outcomes					
	Country	Patient population, sample size	Design & Time horizon	Perspective	Discount rate	Digital health intervention	In combination with other (digital) interventions?	Comparator	Incremental costs [converted to €, 2022]	Incremental effects	ICUR/ICER/ROI [converted to €, 2022]	Authors' conclusion
Augustovski et al. (2018) and Zhang et al. (2021)	Argentina	Hypertension IG: 743 CG: 689	Trial-based 18 months	Public healthcare system	5%	Text-messaging	- Case manager - Physician education	CAU	\$, 2017: 140 [€126]	QALY: 0.042 SBP: -5.30 mmHG Hypertension Control: 19%	\$/QALY: 3299 [€2958] \$/mmHG SBP reduction: 26.43 [€23.70] \$/extra person under threshold: 721 [€646]	Cost-effective
Chen et al. (2016)	USA	Prediabetes IG: 997 CG: 1:1 match with historical cohort	Markov-model Lifetime	Healthcare payer	3%	Website-based intervention including a 16 week online training programme and online social network support communities	- Telemonitoring - Health coach - 24/7 - telephone and online professional network support availability	CAU	\$, 2015 at 3 Y: -800 [€739] \$, 2015 at 5 Y: -3330 [€3076] \$, 2015 at 10 Y: -13,240 [€12,230]	QALY: 0.13	\$/QALY: 4907 [€4400]	Cost-effective
Cunningham et al. (2022)	United Kingdom	T2DM IG: 2576 CG: 5:1 match	Markov model 10 years	Public healthcare system ¹	3.5%	Website and smartphone app for education and access to electronic personal health record for communication with professionals, patient involvement, and shared-decision making.	/	CAU	£, 2018: -84.71 [€106.57]	QALY: 0.054	£/QALY: -1569 [€1974]	Dominant

Table 1 continued

Study	Study characteristics				Intervention		Health economic outcomes					
	Country	Patient population, sample size	Design & Time horizon	Perspective	Discount rate	Digital health intervention	In combination with other (digital) interventions?	Comparator	Incremental costs [converted to €, 2022]	Incremental effects	ICUR/ICER/ROI [converted to €, 2022]	Authors' conclusion
Derakhshandeh-Rishehri et al. (2022)	Iran	Non-insulin dependent T2DM IG: 35 CG: 35 CG2: 35	Trial-based	Patient perspective reported but conflicts with cost overview	/	Web/online nutrition education once a month with internet and WhatsApp training upfront	/	CG1: monthly group sessions with similar education content as IG CG2: CAU (although CAU was non-existing due to Covid-19)	\$, 2021: IG vs CG1: -21,853 [-€18,067] IG vs CG2: 4971 [-€4110]	HbA1c: IG vs CG1: -0.17% IG vs CG2: -0.23%	\$/% HbA1c reduction: IG vs CG1: dominant IG vs CG2: 21,613 [-€17,869]	Cost-effective compared to care as usual
Faleh Al-Mutairi et al. (2021)	Saudi Arabia	T2DM IG: 100 CG: 100	Retro-spective matched cohort study 4 months	Public healthcare system ¹	/	Text-messaging for education and medication management	- Telemonitoring - Teleconsultation	CAU (in-person care, which requires physical attendance at the integrated care clinic)	SAR,2020: 669 [€897]	HbA1c: -0.28%	SAR/% HbA1c reduction: 2373 [€1356]	Cost-effective ³
Gilmer et al. (2019)	Mexico	T2DM IG: 102 CG1: 99 CG2: 99	Markov model Lifetime	Public healthcare system	3%	Text-messaging (and videos)	- Telemonitoring - Teleconsultation - Self-management training - Education of physicians and nurses	CAU+ - CG1: self-management training and education of physicians and nurses - CG2: monthly face-to-face follow-up and option to join a monthly peer support group	\$, 2017: IG vs CG1: 212 [€190] IG vs CG2: 599 [€537]	OALY: IG vs CG1: 0.05 IG vs CG2: 0.22	\$/QALY IG vs CG1: 4299 [€3855] IG vs CG2: 2220 [€1991]	Cost-effective
Islam et al. (2020)	Bangladesh	T2DM IG: 118 CG: 118	Trial-based 6 months	Limited public healthcare system	/	Text-messaging	/	CAU	BDT, 2013: 558 [€21]	OALY: 0.010 HbA1c: -0.64%	BDT/OALY: 55,800 [€2077] BDT/% HbA1c reduction: 871 [€32]	Cost-effective

Table 1 continued

Study	Study characteristics				Intervention		Health economic outcomes			Authors' conclusion		
	Country	Patient population, sample size	Design & Time horizon	Perspective	Discount rate	Digital health intervention	In combination with other (digital) interventions?	Comparator	Incremental costs [converted to €, 2022]		Incremental effects	ICUR/ICER/ROI [converted to €, 2022]
Li et al. (2018)	United Kingdom	T2DM IG: 185 CG: 189	Trial-based 12 months	Public healthcare system	/	- Web: education, social network support, and ask the expert facility. - Text-messaging	/	CAU+ Access to comparator website containing basic information plus education on how to use the website.	£, 2014: 111 [€149]	QALY: 0.020 PAID: -1.9	£/QALY: 5550 [€7454] £/unit improvement on PAID scale: 58 [€78]	Cost-effective
Li et al. (2021)	China	T2DM IG: 130 CG: 85	Trial-based 12 months	Public healthcare system ¹	/	Smartphone app to provide peer support, patient education, telemonitoring and communication with care provider	/	CAU+ Three monthly examination of HbA1c, FBG, and P2BG levels to support medication adjustments. Patient education at each encounter.	CNY, 2019: ² -606 [€149]	Prevalence difference in HbA1c control rate (< 7%): 27.50%	CNY/patient with controlled HbA1c level: -2202 [€540]	Dominant
McManus et al. (2021)	United Kingdom	Hypertension IG: 305 CG: 317	Trial-based 12 months	Public healthcare system ¹	/	Web education	- Telemonitoring of healthcare workers - Education of contacts to support behavioural changes	CAU+ Online patient leaflet for hypertension.	£, 2019: ² 38 [€47]	QALY: 0.002 SBP: -3.5 mmHg	£/QALY: not calculated as QALY difference was insignificant £/unit SBP reduction: 11 [€14]	Cost-effective ³
Tsuji et al. (2020)	Japan	T2DM cohort	Markov model 20 years	Limited public healthcare system	4%	Smartphone app for telemonitoring and communication with care provider and family.	/	CAU	\$, 2018: ² 3634 [€3187]	QALY: 0.11	\$/QALY: 33,039 [€28,971]	Cost-effective

Table 1 continued

Study	Study characteristics				Intervention		Health economic outcomes					
	Country	Patient population, sample size	Design & Time horizon	Perspective	Discount rate	Digital health intervention	In combination with other (digital) interventions?	Comparator	Incremental costs [converted to €, 2022]	Incremental effects	ICUR/ICER/ROI [converted to €, 2022]	Authors' conclusion
Wong et al. (2016)	China	Prediabetes IG:54 CG:50	Markov model Lifetime	Public healthcare system	3%	Text-messaging	/	CAU+ Information booklets on (pre)diabetes and health behaviour.	\$, 2011: -1020 [-€1006] QALY: 0.071 Life years: 0.063		\$/QALY: -14,371 [-€14,177] \$/Life_year: -16,196 [-€15,977]	Dominant
Zhang et al. (2020)	China	Hypertension IG: 101 CG1: 95 CG2: 87	Decision tree model 6 months	Patient	/	Smartphone app to provide patient education, guidance, telemonitoring, health agenda.	/	- CG1: CAU self-management - CG2: CAU+ management	QALY: 0.007 G vs CG1: 15,000 [€3825] IG vs CG2: 295,000 CG2 vs CG1: -485 [-€124]		CNY/QALY: 15,000 [€3825] IG vs CG2: 295,000 CG2 vs CG1: -485 [-€124]	Cost-effective compared to CAU but not compared to CAU+

¹perspective not reported but authors' judgement based on available information; ²reference year not reported so publication year minus two; ³no willingness-to-pay threshold reported or no valid argumentation given why the given willingness-to-pay threshold is justified; CAU care as usual, CG control group, ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio, IG intervention group, QALY quality-adjusted life year, ROI return-on-investment.

T2DM^{27,29,30,32,33,35,37,39}, two included people with prediabetes^{26,34}, and four studies focused on people with hypertension^{28,31,36,38}.

Five studies were within-trial analyses with a time horizon between 6 and 18 months and a public healthcare system perspective^{27,28,31,33,39}, while one was a retrospective matched cohort study applying similar analytics³⁵. The within-trial analysis of Derakshandeh-Rishehri et al.³⁰ applied a patient perspective but this is disputable. One study used a decision tree-based model with a time horizon of 6 months and a patient perspective³⁸. Five studies used a Markov model to estimate long-term (i.e., 10 years to lifetime) costs and effects based on clinical trial inputs, and whereby three applied a public healthcare system perspective^{29,32,34,36} and one a healthcare payer perspective²⁶. Finally, there was one Markov-model study which did not directly stem from one particular implementation study (i.e., all input parameters were literature driven) and which applied a 20-year horizon³⁷. All studies with a time horizon of more than 1 year applied discount rates for both future costs and health outcomes between 3 and 5%^{26,31,32,34,36,37}.

Interventions

Four studies evaluated the use of smartphone applications, one in people with hypertension³⁸ and three in people with T2DM^{29,37,39}. Smartphone applications were used for monitoring, treatment adaptation, and communication between patients and healthcare professionals (in Tsuji et al.³⁷, also for communication with family). The smartphone applications in Li et al.³⁹ and Cunningham et al.²⁹ were also used for patient education. The smartphone application in Zhang et al.³⁸ included a health agenda (i.e., reminders for follow-up). None of the four studies on smartphone applications included non-digital intervention features.

Seven text-messaging^{27,31-36} and five website-based studies²⁶⁻³⁰ were included. One intervention combined text-messaging and websites²⁷, while five other interventions also comprised (non-)digital health modalities such as the implementation of a case manager or teleconsultation^{26,28,31,32,35,36}. Text-messaging was used to encourage the adoption of healthier lifestyle behaviours by participants. The length of the intervention ranged from 16 weeks to 2 years, and the frequency of text messages could be as high as daily but it was not always reported. The website-based intervention component consisted of educational web pages and social network support groups, often in addition to teleconsultation, face-to-face follow-up, and/or telemonitoring.

Interventions were compared to care as usual^{26,29-31,33,35-38} or an enhanced version of care as usual (comprising self-management training, education, and/or physician training)^{27,28,32,38,39}.

Health outcomes

Ten studies reported on the cost per quality adjusted life year (QALY) as the primary health economic outcome^{27-29,31-34,36-38}. Some studies reported clinical outcomes such as systolic blood pressure reduction^{28,31}, HbA1c reduction^{30,33,35}, proportion of population reaching hypertension³¹ or glycemic control³⁹, life years gained³⁴, and points gained on the problem areas in diabetes control (PAID) scale²⁷. The cost-minimisation study of Chen et al.²⁶ reported on the return on investment.

Quality appraisal

Table 2 shows the critical appraisal of selected studies for the evaluation of their quality. More than half of the included studies did not provide sufficient detail on the comparative alternatives (i.e., what does care as usual actually mean). Nine studies did not

Table 2. Quality appraisal with the CHEC-list.

	Augustovski (2018)	Zhang (2021)	Chen (2016)	Cunningham (2022)	Derakhshandeh-Rishehri (2022)	Faleh Al-Mutairi (2021)	Gilmer (2019)	Islam (2020)	Li (2018)	Li (2021)	McManus (2021)	Tsuji (2020)	Wong (2016)	Zhang (2020)	
Study population	0	0	1	1	1	1	0	1	1	1	1	1	1	1	79%
Competing alternatives	0	0	0	0	0	1	1	0	1	1	1	0	0	1	43%
Research question	0	0	0	1	1	0	0	0	1	1	1	0	0	0	36%
Study design	1	1	0	1	0	1	1	1	1	1	1	1	1	1	86%
Time horizon	0	1	1	1	0	0	1	0	0	0	0	1	1	0	43%
Perspective	0	0	0	0	0	0	0	0	1	0	0	0	0	0	7%
Costs: identification	1	1	1	1	0	1	1	0	1	1	0	0	1	1	71%
Costs: measurement	1	1	0	0	0	0	1	0	1	0	0	1	1	1	50%
Costs: value	1	1	0	0	0	0	1	0	1	0	0	1	1	0	43%
Outcomes: identification	1	1	NA	1	1	1	1	1	1	1	1	1	1	1	100%
Outcomes: measurement	1	1	NA	0	1	1	1	1	1	1	1	1	1	1	92%
Outcomes: value	1	1	NA	0	0	0	1	1	1	1	1	1	0	1	77%
Incremental analysis	1	1	NA	1	1	1	1	1	1	1	1	1	1	1	100%
Discounted	1	1	1	1	NA	NA	1	NA	NA	NA	NA	1	1	NA	100%
Sensitivity analysis	1	1	0	1	0	0	1	0	1	0	1	0	0	0	43%
Conclusions	1	1	1	1	0	1	0	0	1	1	1	0	1	1	71%
Generalizability	0	1	1	1	1	1	1	1	1	0	1	1	0	0	71%
No conflict of interest	1	1	0	0	1	1	1	1	1	1	0	0	1	1	71%
Ethics	1	1	0	1	0	0	0	1	1	0	1	0	0	1	50%
Quality score (%)	68	79	40	63	42	56	74	50	94	61	67	58	63	67	

More extensive item assessment instructions can be found in Appendix 3. NA not applicable.

describe important costing aspects such as how the costs were measured or the sources of cost valuation^{26,28–30,33,35,37–39}. A rather short time horizon was applied in more than half of the studies^{27,28,30,31,33,35,38,39} despite a long-time horizon being recommended in evaluating cost-effectiveness of chronic diseases to capture all relevant costs and effects. Moreover, all but one study²⁷ did not provide sufficient argumentation for choosing another perspective to the societal one. Finally, only six studies reported both probabilistic sensitivity results plus another kind of sensitivity analysis such as threshold analysis or one-way sensitivity analysis on top of the point estimate results^{27–29,31,32,36}.

Data synthesis

Among the studies expressing results in QALYs, the ICURs varied between dominant (i.e., less costly and better health outcomes) and €75,233/QALY, with a median of €3840/QALY (interquartile range €16,179). One study did not find a QALY difference (Fig. 2). None of the three digital health intervention modes was associated with substantially better cost-effectiveness results than the others. Four out of fourteen studies (one on text messaging, two on mainly smartphone applications, and one on website-based education) reported cost-saving results^{26,29,34,39}.

Smartphone applications were appraised by the studies' authors as cost-effective^{37,38} or dominant^{29,39} compared to usual care. However, the cost-effective results in Tsuji et al.³⁷ were associated with considerable uncertainty and should be confirmed by future trial data, as effectiveness data were simulated and the prediction model had been built on major assumptions. Li et al.³⁹

did not report uncertainty analyses. Furthermore, the smartphone application in Zhang et al.³⁸ was reported as not cost-effective compared to a self-management intervention: QALY gain was higher but at a considerable cost: a self-management strategy appeared to be the preferred strategy from a health economic perspective (Fig. 2).

Text-messaging alone, or in combination with other intervention aspects (such as teleconsultation, telemonitoring, case management), was found to be cost-effective^{27,31–33,35,36} or even cost-saving³⁴. Although QALY gains were limited (ranging from a 0.01 increment per target person after 6 months in Islam et al.³³ to a 0.22 increment per target person taking a lifetime horizon in Gilmer et al.³²), the ICUR appeared to be robust in probabilistic sensitivity analysis^{27,31,32,36}. This can be related to the low intervention costs since Islam et al.³³ demonstrated that programme costs could at least be doubled while remaining cost-effective. Wong et al.³⁴ even calculated that programme costs could be 50 times greater before the break-even point would be reached. Moreover, Li et al.²⁷ argued that the health economic results of text-messaging can be even further improved by upscaling so that the cost per person decreases. Importantly, the ICUR in Gilmer et al.³² turned cost-effective only after 10–20 years, which was inconsistent with other studies that demonstrated cost-effectiveness in the short term^{27,31,33}.

Website-based interventions appeared to be cost-effective^{27,28,30}, dominant²⁹, or cost-saving²⁶, even though only a natural effect (i.e., a reduction in systolic blood pressure; the incremental number of QALYs was not significant) was found in the study by McManus et al.²⁸. Yet scenario analysis, in which the

intervention effect partly faded away, and probabilistic sensitivity analyses showed the results to be robust at given thresholds^{26–29}.

Sensitivity and subgroup analyses were limited in most studies, which restricts the identification of cost-effectiveness drivers. First, Augustovski et al.³¹ reported on patient baseline characteristics: the intervention appeared to have greater value for money in populations of younger age, subjects with higher cardiovascular risk, higher body mass index, and women. The gender difference has been reported by Cunningham et al.²⁹ as well.

Secondly, intervention aspects influenced the ICER/ICUR as well. A less intensive so less costly intervention following lower treatment adherence was reported by Augustovski et al.³¹, thus being indicative of better cost-effectiveness although the observed differences were not statistically significant. Meanwhile drop-out rates did not impact the ICER/ICUR in Wong et al.³⁴. Costs were important drivers of cost-effectiveness in other studies as well^{33,38}.

Third, modelling assumptions was the third and most investigated pillar of what drives cost-effectiveness results. The value for money improved with longer time horizons^{26,32}, and the impact of transition probabilities, utility values, and discount rate on the ICUR were mixed^{34,37,38}.

Whether digital health interventions targeting (pre)T2DM versus hypertension populations resulted in different cost-effectiveness outcomes, is difficult to assess because only three studies targeted populations with hypertension. However, it seems that digital health interventions targeting (pre)T2DM populations showed consistently positive cost-effective results^{26,27,29,30,32–35,37,39}, while cost-effectiveness results in hypertension populations were more mixed^{28,31,36,38}.

Whereas six studies evaluated one particular digital health mode, there were two studies that combined two of the digital health modes under investigation^{27,29}, two studies where the digital health mode was part of a broader digital intervention including telemonitoring^{26,35}, and four studies (three interventions) where the digital health mode was part of a broader health system intervention including digital and non-digital components^{28,31,32,36}. Website-interventions, text messaging, and smartphone applications were complemented by, or were seen as a complement of, other intervention components in four out of five, four out of six, and one out of four times, respectively. Gilmer et al.³² and Zhang et al.³⁶ evaluated two of the broader health system interventions and found relatively higher health effects (0.22 and 0.13 QALYs, respectively) compared to stand-alone

interventions. Note that these two studies applied a long-term perspective, contrary to McManus et al.²⁸ who evaluated a broad health system intervention and who found only a systolic blood pressure reduction on the short-term but no QALY improvement.

DISCUSSION

This review aimed to synthesize the available health economic evidence of digital health interventions in populations with or at risk of T2DM and/or hypertension. Digital health interventions were restricted to smartphone applications, text-messaging, and website-based interventions. The three digital health intervention modes were found to be cost-effective or cost-saving compared to care as usual and, most of the time, to enhanced care as usual too. Median ICUR of cost-utility studies was low with €3840/QALY.

Recent meta-analyses from our team have shown the three digital health interventions to be equally effective in reducing BP in adults with hypertension, while text-messaging and smartphone application interventions were associated with increased improvements in glycaemic control compared to website-based interventions in adults with T2DM^{19,20}. However, increased effects did not always offset additional costs: when comparing the three digital intervention modes with (enhanced) care as usual, our analysis did not show a strong preference in terms of cost-effectiveness for one particular mode.

Digital health interventions seem to be consistently cost-effective in populations with (pre)T2DM but not in populations with hypertension. One possible explanation could be that the cost-effectiveness of implementing a digital health mode depends on the perceived severity of a condition and hence the urge to act upon. Hypertension is so widespread that some might perceive it merely as a risk factor instead of a disease⁴⁰, so patients and professionals could be less motivated to do something about it. For example, New Zealand does not have hypertension guidelines but bases its care recommendations on a cardiovascular risk score⁴¹. Moreover, a global consensus definition of hypertension is lacking (see for example the definitions of different leading organisations: <https://tinyurl.com/whohyp>, <https://tinyurl.com/cdchyp>, <https://tinyurl.com/mayhyp>, <https://tinyurl.com/nhshypdef>). Smartphone applications, websites and text-messaging may have a significant clinical impact on BP, but there are possibly other approaches or other health objectives that better justify the money invested. This remains to be tested as the health economic evidence of smartphone apps, text-messaging,




Fig. 2 Incremental cost-utility results (ICUR) estimates of included studies. Note that McManus et al.²⁸ did not calculate an ICUR as QALY difference was insignificant. ICUR estimates in Cunningham et al.²⁹ and Wong et al.³⁴ were dominant. CG control group. *: asterisk denotes studies targeting populations with hypertension; studies without an asterisk include people with (pre)diabetes.

and website-based interventions in populations with hypertension remains very limited.

Among other process evaluation constructs, adherence and reach are two important ones with a major impact on digital health interventions' cost-effectiveness⁴². Patients who adhere with a smartphone application showed, for instance, better medication adherence⁴³. However, high drop-out rates of 40% (95% CI 16–63%) in RCT's testing smartphone applications have been demonstrated as well⁴⁴. It has been suggested that attrition could, for instance, be reduced by using user feedback to enhance user experience, by enabling the possibility for users to contact health professionals (a so-called hybrid model), by focusing on self-management skills, by increasing health literacy, and by combining smartphone applications with internet or telehealth solutions⁴⁴.

Differentiating between primarily digital health interventions and primarily health system interventions with a digital component is warranted. Our results suggest that health system interventions might have the potential to gain more health effects on the long-term compared to a stand-alone digital health mode intervention, although current evidence is limited and mixed. However, Augustovski et al.³¹ suggested better cost-effectiveness when the intervention was less intense. Although their statement should be interpreted cautiously because of overlapping confidence intervals between the different intervention intensities, these observations might be in line with the results of a meta-analysis on drop-out rates of exercise interventions that demonstrated a higher likelihood of drop-out in more intensive interventions⁴⁵. Therefore, future interventions should carefully consider which features need to be combined, knowing that more intervention features could improve effectiveness but a too intense intervention may also increase complexity of use thus having a detrimental impact on both drop-out and cost-effectiveness. Participant input via co-design may be of a help from the evidence gathering to the real-world testing stage⁴⁶.

Given that there are hundreds of millions of people with or at risk of T2DM and hypertension, it is important to keep an eye on the scalability and budget impact of a new programme⁴². Whereas clinical effectiveness on the individual level can be optimised by adding possible intervention components to tailor care, less elaborated programmes may have a higher reach resulting in more population benefit within a closed budget. This could be of particular importance to digitally less-developed countries where digital interventions might be relatively more expensive. Scrutinizing the optimal intervention dose in different health systems including digitally less-developed countries is therefore paramount. Our results indicate for instance that text-messaging is appraised as cost-effective across studies, either in combination with other intervention features or not. Self-monitoring can also be a very powerful strategy to improve cost-effectiveness as well. It might therefore be an option to integrate such functionalities in smartphone applications.

Our quality appraisal demonstrated important methodological shortcomings. Based on these, our four key lessons for future health economic evaluations of digital health interventions are:

1. Health economic results can only be appraised correctly with an elaborate research question and sufficient context. The competing alternatives under investigation – care as usual in particular – should be detailed. The study's perspective should be justified and the applied time horizon should capture relevant long-term costs and effects of preventive measures^{9,11}. In this regard, it is important to stress the cost-effectiveness results of digital therapeutics despite the sometimes quite short time horizons applied.
2. Transparency is pivotal when reporting applied costs: which costs have been included exactly (which refers to the perspective) and how these were measured and valued

should be stated.

3. Health economic evaluations of digital health interventions often come with data uncertainty and assumptions. One-way and probabilistic sensitivity analyses are at least needed to address these uncertainties, preferably in different subgroups. Following key lesson 1 on applying an appropriate long time horizon, it is pivotal to scrutinize the impact of the intervention effect's sustainability on the health economic outcome, especially given the high attrition and dropout rates in for instance app-based interventions⁴⁴.
4. An ICUR does not have an intrinsic value and should always be evaluated in light of a willingness-to-pay threshold. Most included studies applied a threshold value of one to three times the gross domestic product (GDP) per capita, as recommended by the World Health Organisation^{47,48}, but critics argued that a more conservative threshold of $\pm 50\%$ the GDP per capita would better capture opportunity costs^{48,49}. Note that, given such a conservative threshold, most cost-effectiveness estimates of digital health interventions remain cost-effective. Furthermore, some studies applied natural units (e.g., cost per percentage HbA1c reduction). For instance, Derakhshandeh-Rishehr et al.³⁰, Faleh Al-Mutairi et al.³⁵ and McManus et al.²⁸ reported an increase in health effect at an increased cost and stated the result was cost-effective although no willingness-to-pay threshold or valid argumentation for the applied willingness-to-pay threshold was reported, respectively.

These key lessons should be considered in future research. Such studies should also strive to address evidence gaps in the field. Head-to-head studies are definitely needed to determine the digital health mode with the best value for money in different subgroups operating within a particular health system. The uncertainty associated with long-term health economic evaluations can be reduced by designing trials with longer clinical follow-up periods so the sustainability of the intervention effect can be modelled more precisely. Moreover, budget impact estimates are truly relevant for policy makers given the high prevalence of T2DM and hypertension, while uptake and attrition rates should also be taken into consideration as they can also have a significant effect on the costs.

The most important strengths of this review are the complementarity with previously published meta-analyses^{19,20} scrutinizing the effectiveness of the three digital health intervention modes, and the thorough quality appraisal resulting in several key lessons for health economic research.

However, this systematic review also has limitations. First, the adult filter is not consistent between the five searched databases. In Medline, the adult filter is >19 years of age, whereas for EMBASE and PsycINFO it is >18. However, the proportion of the population with T2DM or hypertension at that age is small^{50,51}. Second, studies on people with or at risk of T2DM or hypertension were included but the small number of studies impeded appropriate subgroup analyses. What may work in one population may not work in another. Third, only English articles were included and this may limit our conclusions, especially since T2DM and hypertension prevalence are high in large non-English-speaking countries such as India⁵² and China⁵³. However, included studies from the Americas, Europe, Asia, and the Middle-East reflected a geographically and demographically diverse population. Fourth, digital health solutions in five website-based or text-messaging studies have been augmented with other intervention features such as healthcare professional education, telemonitoring and/or (tele) consultations. It is therefore not clear whether the intervention effect arises due to these additional intervention features or due to the digital intervention component. Fifth, the number of full health economic papers remain scarce, especially compared to the accumulating amount of clinical effectiveness evidence, and the

results of Tsuji et al.³⁷ are based on disputable assumptions. Because of the low number of included papers, additional analyses of the impact of study quality on results were not conducted. Sixth, no head-to-head health economic studies of the three digital intervention modes were found. Seventh, health economic studies might be subject to multiple sources of publication bias including a publication bias in first health outcome publications and next economic publications. Funnel plotting to investigate possible publication bias was not an option in this study but Moschonis et al.¹⁹ and Siopis et al.²⁰ demonstrated respectively a small and non-existing publication bias in our health outcome reviews. It is of course still possible that a publication bias favoring cost-effective or cost-saving results remains in economic publications, especially given the suboptimal reporting of sensitivity analyses⁵⁴.

In conclusion, health economic evidence suggests that smartphone application, text-messaging, and website-based interventions are cost-effective and, in some cases, even cost-saving. It shows how challenging, but at the same time how possible, it can be to improve the health of the population while saving money.

While previous research demonstrated that the three digital health intervention modes were equally clinically-effective in adults with hypertension, and that text-messaging and smartphone application interventions worked significantly better than website-based interventions in adults with T2DM, no cost-effectiveness evidence was found supporting one particular digital health intervention mode over another. Moreover, text-messaging, smartphone application, and website-based interventions appeared to be consistently cost-effective in populations with (pre)T2DM, but not in populations with hypertension.

Based on the available evidence, policy makers and clinicians should make decisions on the most appropriate digital health interventions based on available budgets and well-defined health objectives. The high penetration rate of digital applications in diverse populations is a strength but it is pivotal to keep process evaluation constructs in mind. Key lessons for future health economic studies on how to design studies and report on the results are given. It is important to pay special focus on the context, report the costs included and how these were measured and valued, conduct sufficient sensitivity analyses, and appraise the cost-effectiveness result more critically in light of a reasoned willingness-to-pay threshold. Head-to-head studies are missing while this would enhance understanding and practice substantially. It is strongly recommended to consistently include a cost-effectiveness work package alongside clinical trials⁵⁵.

METHODS

Literature search

The protocol (PROSPERO CRD42021247845) and reporting of this systematic review were consistent with the 2020 PRISMA guidelines⁵⁶. Five electronic databases (Medline via Ovid, Embase via embase.org, CENTRAL via cochranelibrary.com, CINAHL via EBSCO, and APA PsycInfo via Proquest) were systematically searched for scientific publications on September 2, 2022. The applied search strategy consisted of population-related and intervention-related keywords, developed by Moschonis et al.¹⁹ and Siopis et al.²⁰, combined with a search string to detect economic evaluations, developed by Werbrouck et al.⁵⁷. The latter was originally based on previously published search strings. References^{58,59}, but was broadened to maximize sensitivity⁵⁷. The search strategy is further completely consistent with Moschonis et al.¹⁹ and Siopis et al.²⁰ the literature search was restricted by age (adults only), publication date (1 January 2009 onwards to include contemporary evidence only), and language (English), if the search engine allowed to do so. The search strategies for CENTRAL and CINAHL were further restricted to trials only and peer-reviewed

manuscripts, respectively. The final search string can be found in Supplementary Methods 1. The search terms and inclusion criteria targeted a broad spectrum of studies with digital components to maximize detection rate. However, only studies with at minimum a smartphone application, text-messaging, or website-based intervention were eventually withheld. Backward and forward citation tracking were performed to identify any studies missed by the search strategy.

As this study is a systematic review, ethical approval was not applicable.

Study selection and data extraction

Titles and abstracts were screened with Rayyan⁶⁰ by two independent reviewers (RW and NV) based on a priori developed eligibility criteria (Table 3). Importantly, not only head-to-head studies directly comparing the three digital health modes were included, but studies comparing the intervention including a digital health mode to usual care were included as well. Discrepancies were discussed between the two reviewers until consensus was reached. A third reviewer (LA) was available but did not have to step in as there were no discrepancies left.

Eligible full texts were screened by the first author (RW) and one-third of these full texts were screened by a second author (NV). Reference lists from articles that fitted the inclusion criteria were checked for missed articles. The following predetermined data were extracted from all included articles:

- General study characteristics: publication year, country, participant characteristics, intervention alternatives;
- Methods: study perspective (i.e., point of view), economic evaluation type, analytic approach, time horizon (i.e., period of analysis), discount rate (i.e., to convert a value received in the future to a value today), reference year of costs, willingness-to-pay threshold (i.e., what is society prepared to pay for health), intervention costs, health resource use and data sources, information regarding the base case and sensitivity analyses;
- Results and conclusion: (incremental) costs and effects, results from sensitivity analyses, author's conclusions.

Quality appraisal

As recommended by van Mastrigt et al.⁶¹, study quality has been appraised with the Consensus on Health Economic Criteria (CHEC) list⁶², since this checklist enables the assessment of both trial- and model-based economic evaluations^{25,61}. The two independent reviewers (RW and NV) followed Werbrouck et al.⁵⁷, who suggested small adaptations to the checklist (e.g., 'not applicable' was a valid answer option next to yes or no: for instance, whether or not discounting (item 14) was applied, was only considered applicable if a study's time horizon was >1 year. Such adaptations resulted in a more valid appraisal of individual studies' quality)⁵⁷. Discrepancies were discussed by the two reviewers until consensus was reached by specifying assessment criteria.

Evidence table and analysis

The evidence table summarises study characteristics, treatment alternatives, and results from the incremental base case analyses. Sensitivity analyses are addressed in text. The following methodology applies:

- The treatment in the comparator group has been dichotomised into care as usual (CAU) and enhanced care as usual (CAU +). In the case of the latter, further description was provided.
- Perspective could either be (i) the public healthcare system perspective (i.e., the third-party payer perspective), (ii) the healthcare payer perspective (i.e., including patient costs next to third-party payer costs), (iii) the societal perspective (i.e.

Table 3. Eligibility criteria.

	Inclusion criteria	Exclusion criteria
Population	Adults with or at risk of T2DM and/or hypertension	Children, adolescents, mixed patient populations without stratified results.
Intervention	Smartphone applications, text-messaging, or website interventions	Other digital health interventions (e.g. teleconsultation only, telemonitoring without the use of a smartphone app).
Comparator	Care as usual, face-to-face intervention etc.	N.A.
Outcomes	Full economic outcomes (e.g. cost-effectiveness; cost-utility analysis) or studies capturing both intervention and health resource use costs (cost minimisation).	Outcomes related to either effectiveness, intervention costs, or health resource use costs only.
Publication type and study design	Original research: model-based or within-trial health economic evaluations	Pre/post, reports, systematic reviews, meta-analyses, congress abstracts, protocols, commentaries, animal studies
Language	English	Other languages
Published date	2009 to present	Before 2009

N.A. not applicable, T2DM type 2 diabetes mellitus.

including the payer perspective and costs from productivity losses), (iv) the patient perspective, or (v) the organisational perspective. In the case that the perspective was not explicitly stated, the authors made a judgement. A perspective could also be called 'limited': a limited societal perspective may for instance account for non-medical costs (i.e., costs such as transport costs to the hospital, which are costs outside the healthcare sector, but directly relatable to the disease) but not for indirect non-medical costs (i.e., productivity losses due to absenteeism or presenteeism).

- In order to improve the comparability between studies from different countries and different reference years⁶¹, costs and incremental cost-effectiveness ratios (ICERs)/incremental cost-utility ratios (ICURs) were converted via an online calculator (<https://epi.ioe.ac.uk/costconversion/>) to 2022 Euro currency values with Belgium as the reference country, to account for purchasing power parities.

Results were analysed together and per delivery mode, disease, and outcome measure. Moreover, possible cost-effectiveness drivers were explored.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

Template data collection form and full data extracted from included studies will be made publicly available on The Open Science Framework under 'DigiCare4You health economics'.

Received: 27 February 2023; Accepted: 7 July 2023;

Published online: 18 August 2023

REFERENCES

1. IDF. *IDF Atlas 10th edn* (International Diabetes Federation, 2021).
2. Morris, D. H. et al. Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. *Diabetologia* **56**, 1489–1493 (2013).
3. Sowers, J. R., Epstein, M. & Frohlich, E. D. Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension (Dallas, Tex. : 1979)* **37**, 1053–1059 (2001).
4. Mills, K. T., Stefanescu, A. & He, J. The global epidemiology of hypertension. *Nat. Rev. Nephrol.* **16**, 223–237 (2020).
5. Egan, B. M. & Stevens-Fabry, S. Prehypertension—prevalence, health risks, and management strategies. *Nat. Rev. Cardiol.* **12**, 289–300 (2015).
6. Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease Prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur. Heart J.* **37**, 2315–2381 (2016).
7. Huang, X. L. et al. Efficacy of lifestyle interventions in patients with type 2 diabetes: a systematic review and meta-analysis. *Eur. J. Intern. Med.* **27**, 37–47 (2016).
8. Alouki, K., Delisle, H., Bermúdez-Tamayo, C. & Johri, M. Lifestyle interventions to prevent type 2 diabetes: a systematic review of economic evaluation studies. *J. Diabetes Res.* **2016**, 2159890 (2016).
9. Roberts, S. et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. *BMJ Open* **7**, e017184 (2017).
10. Li, R. et al. Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the community preventive services task force. *Ann. Intern. Med.* **163**, 452–460 (2015).
11. Willems, R. et al. Cost-effectiveness analysis of a school- and community-based intervention to promote a healthy lifestyle and prevent type 2 diabetes in vulnerable families across Europe: the Feel4Diabetes-study. *Prev. Med.* **153**, 106722 (2021).
12. Steinhubl, S. R., Muse, E. D. & Topol, E. J. Can mobile health technologies transform health care? *JAMA* **310**, 2395–2396 (2013).
13. Bankmycell.com. *How Many Smartphones are in the World?* <https://www.bankmycell.com/blog/how-many-phones-are-in-the-world> (2022).
14. Choi, W., Wang, S., Lee, Y., Oh, H. & Zheng, Z. A systematic review of mobile health technologies to support self-management of concurrent diabetes and hypertension. *J. Am. Med. Inf. Assoc.* **27**, 939–945 (2020).
15. Zhai, Y. K., Zhu, W. J., Cai, Y. L., Sun, D. X. & Zhao, J. Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis. *Med. (U. S.)* **93**, e312 (2014).
16. Wang, Y. et al. Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews. *JMIR Mhealth Uhealth* **8**, e15400 (2020).
17. Li, R., Liang, N., Bu, F. & Hesketh, T. The effectiveness of self-management of hypertension in adults using mobile health: systematic review and meta-analysis. *JMIR Mhealth Uhealth* **8**, e17776 (2020).
18. Khoong, E. C. et al. Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses. *NPJ Digit. Med.* **4**, 114 (2021).
19. Moschonis, G. et al. Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with type 2 diabetes: A systematic literature review and meta-analysis of randomised controlled trials. *Lancet Digit. Health* **5**, e125–e143 (2023).
20. Siopis, G. et al. Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with hypertension: A systematic literature review and meta-analysis of randomised controlled trials. *Lancet Digit. Health* **5**, e144–e159 (2023).

21. WHO. mHealth: new horizons for health through mobile technologies: based on the second global survey on eHealth. in *Global Observatory for eHealth*, Vol. 3 (World Health Organization, Geneva, 2011).
22. Iribarren, S. J., Cato, K., Falzon, L. & Stone, P. W. What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. *PLoS One* **12**, e0170581 (2017).
23. Rinaldi, G., Hijazi, A. & Haghparast-Bidgoli, H. Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: a systematic review. *Diabetes Res. Clin. Pract.* **162**, 108084 (2020).
24. Morris, T., Aspinall, F., Ledger, J., Li, K. & Gomes, M. The impact of digital health interventions for the management of type 2 diabetes on health and social care utilisation and costs: a systematic review. *Pharmacoecon Open* **7**, 163–173 (2022).
25. Wijnen, B. et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). *Expert Rev. Pharmacoecon. Outcomes Res.* **16**, 723–732 (2016).
26. Chen, F. et al. Clinical and economic impact of a digital, remotely-delivered intensive behavioral counseling program on medicare beneficiaries at risk for diabetes and cardiovascular disease. *PLoS One* **11**, e0163627 (2016).
27. Li, J. et al. Cost-effectiveness of facilitated access to a self-management website, compared to usual care, for patients with type 2 diabetes (HeLP-diabetes): randomized controlled trial. *J. Med. Internet Res.* **20**, 1–15 (2018).
28. McManus, R. J. et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. *BMJ* **372**, m4858 (2021).
29. Cunningham, S. G. et al. Cost-utility of an online education platform and diabetes personal health record: analysis over ten years. *J. Diabetes Sci. Technol.* **17**, 715–726 (2022).
30. Derakhshandeh-Rishehri, S. M., Keshavarz, K., Ghodsi, D., Pishdad, G. & Faghih, S. Cost-effectiveness analysis of group vs. Weblog Telecommunication (Web Tel) nutrition education program on glycemic indices in patients with non-insulin dependent diabetes mellitus type 2: a randomized controlled trial. *Front. Nutr.* **9**, 915847 (2022).
31. Augustovski, F. et al. Cost-effectiveness of a comprehensive approach for hypertension control in low-income settings in Argentina: trial-based analysis of the hypertension control program in Argentina. *Value Health* **21**, 1357–1364 (2018).
32. Gilmer, T., Burgos, J. L., Anzaldo-Campos, M. C. & Vargas-Ojeda, A. Cost-effectiveness of a technology-enhanced diabetes care management program in Mexico. *Value Health Reg. Issues* **20**, 41–46 (2019).
33. Islam, S. M. S. et al. Cost-effectiveness of a mobile-phone text messaging intervention on type 2 diabetes—a randomized-controlled trial. *Health Policy Technol.* **9**, 79–85 (2020).
34. Wong, C. K. et al. Cost-effectiveness of a short message service intervention to prevent type 2 diabetes from impaired glucose tolerance. *J. Diabetes Res.* **2016**, 1219581 (2016).
35. Faleh AIMutairi, M. et al. Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia. *Ther. Adv. Chronic Dis.* <https://doi.org/10.1177/204062232110425> (2021).
36. Zhang, Y. et al. Cost-effectiveness of a multicomponent intervention for hypertension control in low-income settings in Argentina. *JAMA Netw. Open* **4**, e2122559 (2021).
37. Tsuji, S. et al. Cost-effectiveness of a continuous glucose monitoring mobile app for patients with type 2 diabetes mellitus: analysis simulation. *J. Med. Internet Res.* **22**, e16053 (2020).
38. Zhang, X. et al. Cost-effectiveness analysis of different hypertension management strategies in a community setting. *Intern. Emerg. Med.* **15**, 241–250 (2020).
39. Li, J., Sun, L., Hou, Y. & Chen, L. Cost-effectiveness analysis of a mobile-based intervention for patients with type 2 diabetes mellitus. *Int. J. Endocrinol.* **2021**, 8827629 (2021).
40. Jackson, R. & Wells, S. Time to remove hypertension from our vocabulary? *Lancet (Lond., Engl.)* **398**, 1023–1025 (2021).
41. The, L. Is the concept of hypertension as a disease unhelpful? *Lancet (Lond., Engl.)* **394**, 611 (2019).
42. Oldenburg, B., Taylor, C. B., O'Neil, A., Cocker, F. & Cameron, L. D. Using new technologies to improve the prevention and management of chronic conditions in populations. *Annu. Rev. Public Health* **36**, 483–505 (2015).
43. Pérez-Jover, V., Sala-González, M., Guilabert, M. & Mira, J. J. Mobile apps for increasing treatment adherence: systematic review. *J. Med. Internet Res.* **21**, e12505 (2019).
44. Meyerowitz-Katz, G. et al. Rates of attrition and dropout in app-based interventions for chronic disease: systematic review and meta-analysis. *J. Med. Internet Res.* **22**, e20283 (2020).
45. Jabardo-Camprubí, G., Donat-Roca, R., Sitjà-Rabert, M., Milà-Villaruel, R. & Bort-Roig, J. Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: a systematic review and meta-analysis. *Physiol. Behav.* **215**, 112786 (2020).
46. Eyles, H. et al. Co-design of mHealth delivered interventions: a systematic review to assess key methods and processes. *Curr. Nutr. Rep.* **5**, 160–167 (2016).
47. WHO. *Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development* (World Health Organization, Geneva, 2001).
48. Bertram, M. Y. et al. Cost-effectiveness thresholds: pros and cons. *Bull. World Health Organ.* **94**, 925–930 (2016).
49. Woods, B., Revill, P., Sculpher, M. & Claxton, K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. *Value Health* **19**, 929–935 (2016).
50. Lawrence, J. M. et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001–2017. *JAMA* **326**, 717–727 (2021).
51. Song, P. et al. Global prevalence of hypertension in children: a systematic review and meta-analysis. *JAMA Pediatr.* **173**, 1154–1163 (2019).
52. Abariga, S. A., Khachan, H. & Al Kibria, G. M. Prevalence and determinants of hypertension in India based on the 2017 ACC/AHA guideline: evidence from the India National Family Health Survey. *Am. J. Hypertens.* **33**, 252–260 (2020).
53. Bragg, F. & Chen, Z. Estimating lifetime risk of diabetes in the Chinese population. *PLoS Med.* **19**, e1004053 (2022).
54. Mandrik, O. L. et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report. *Value Health* **24**, 463–472 (2021).
55. Ramsey, S. D. et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR good research practices task force report. *Value Health* **18**, 161–172 (2015).
56. Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* **372**, n71 (2021).
57. Werbrouck, A. Disease prevention and health promotion in Flanders : health economic evidence to support healthcare decision making. (Ghent University and University of Leuven, 2021).
58. Neyt, M. & Chalon, P. X. Search MEDLINE for economic evaluations: tips to translate an OVID strategy into a PubMed one. *Pharmacoeconomics* **31**, 1087–1090 (2013).
59. University of York. *Search Strategies* (University of York, 2018).
60. Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan—a web and mobile app for systematic reviews. *Syst. Rev.* **5**, 210 (2016).
61. van Mastrigt, G. A. et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). *Expert Rev. Pharmacoecon. Outcomes Res.* **16**, 689–704 (2016).
62. Evers, S., Goossens, M., de Vet, H., van Tulder, M. & Ament, A. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. *Int. J. Technol. Assess. Health Care* **21**, 240–245 (2005).

ACKNOWLEDGEMENTS

The DigiCare4You study has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 945246. G.S., G.M., D.K. and B.O. received funding from the National Health and Medical Research Council (NHMRC) of Australia, as part of the NHMRC European Union Collaborative Research Grant Scheme, under the agreement with the NHMRC ID APP2007006. R.V. declares receipt by New York University Grossman School of Medicine of a DigiCare4You funding subaward. The content of this article reflects only the authors' views, and the European Union is not liable for any use that may be made of the information contained therein. The funding source had no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, or in the decision to submit for publication.

AUTHOR CONTRIBUTIONS

Conceptualisation: R.W., N.V., Y.M., L.A.; methodology: R.W., N.V., L.A.; data collection: R.W., N.V.; data analysis: R.W., N.V., L.A.; writing-original draft preparation: R.W.; writing-review and editing: all authors; supervision: L.A., G.M.; project administration: R.W., G.S.; funding acquisition: R.W., G.M., L.A., B.O., Y.M. All authors have read and agreed to the final version of the manuscript.

COMPETING INTERESTS

L.A. received consulting fees from Mundipharma for advice on cost-effectiveness of SGLT2 inhibitors for the management of type 2 diabetes; honoraria from Boehringer Ingelheim and Mundipharma for lectures on health economic aspects of diabetes; is a member of the board of the AstraZeneca Foundation. C.d.A. and S.G. are employees of the company Meteda, manufacturer of MetaClinic, DiaWatch METEDA, MetaDieta and MyDiet. All other authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41746-023-00876-x>.

Correspondence and requests for materials should be addressed to Ruben Willems.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

DIGICARE 4YOU

Ruben Willems¹✉, Lieven Annemans¹, George Siopis^{2,3}, George Moschonis², Rajesh Vedanthan⁴, Jenny Jung⁵, Dominika Kwasnicka^{6,7}, Brian Oldenburg⁶, Claudia d'Antonio⁸, Sandro Girolami⁸, Eirini Agapidaki⁹, Yannis Manios^{10,11}, Nick Verhaeghe¹, Natalya Usheva¹², Violeta Iotova¹², Andreas Triantafyllidis¹³, Konstantinos Votis¹³, Florian Toti¹⁴, Konstantinos Makrilakis¹⁵, Chiara Seghieri¹⁶, Luis Moreno¹⁷, Sabine Dupont¹⁸, Leo Lewis¹⁹, Djordje Djokic²⁰ and Helen Skouteris²¹

¹²Medical University of Varna, Varna, Bulgaria. ¹³Centre for Research and Technology Hellas – Information Technologies Institute, Hellas, Greece. ¹⁴University of Medicine, Tirana, Albania. ¹⁵National and Kapodistrian University of Athens, Athens, Greece. ¹⁶Sant'Anna School of Advanced Studies, Pisa, Italy. ¹⁷Universidad de Zaragoza, Zaragoza, Spain. ¹⁸International Diabetes Federation European Region, Brussels, Belgium. ¹⁹International Foundation of Integrated Care, Schiphol, The Netherlands. ²⁰Privanova, Paris, France. ²¹Monash University, Melbourne, Australia. A full list of members and their affiliations appears in the Supplementary Information.